Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022
Introduction: Over 400 million patients worldwide suffer from rare diseases. Access to orphan drugs is, therefore, crucial for this population. China has been actively working on improving orphan drug accessibility in the past decades, especially since 2018 when the First National List of Rare Disea...
Main Authors: | Jia Liu, Yue Yu, Mingkang Zhong, Chunlai Ma, Rong Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1138996/full |
Similar Items
-
Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01) -
Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges
by: Luyao Qiao, et al.
Published: (2022-09-01) -
Orphan drugs in Italy: availability and time-to-access at regional level
by: Maria Lucia Marino, et al.
Published: (2023-12-01) -
Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01) -
Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
by: ZHANG Shan, et al.
Published: (2023-04-01)